Table 2—

Results before and 32 weeks after treatment with rosiglitazone and insulin or placebo and insulin

Rosiglitazone and insulin
Placebo and insulin
BaselineWeek 32BaselineWeek 32
Weight (kg)97.2 ± 11.8100.6 ± 16.0*96.4 ± 12.299.1 ± 15.0*
BMI (kg/m2)32.7 ± 5.434.0 ± 7.4*31.1 ± 3.132.0 ± 4.2*
Systolic blood pressure (mmHg)137.4 ± 15.6128.8 ± 14.8*125.8 ± 10.0127.5 ± 14.0
Diastolic blood pressure (mmHg)87.2 ± 9.479.4 ± 7.284.7 ± 7.083.2 ± 7.1
Insulin dose (units/day)77.5 ± 28.675.3 ± 33.174.0 ± 33.882.0 ± 48.9*
Fasting plasma glucose (mg/dl)172.6 ± 68.3153.3 ± 66.4185.8 ± 90.6173.4 ± 64.8
A1C (%)7.9 ± 1.36.9 ± 0.77.7 ± 0.87.0 ± 0.9
Total cholesterol (mg/dl)201.9 ± 37.6195.2 ± 37.5§177.9 ± 33.1175.1 ± 31.7
LDL cholesterol (mg/dl)117.8 ± 32.0120.1 ± 35.0103.4 ± 25.2102.6 ± 25.4
HDL cholesterol (mg/dl)53.9 ± 20.553.6 ± 19.447.8 ± 15.049.1 ± 15.8
VLDL cholesterol (mg/dl)15.8 ± 13.216.4 ± 9.813.8 ± 9.414.6 ± 15.6
Triglycerides (mg/dl)108.1 ± 64.6101.8 ± 53.892.8 ± 38.985.4 ± 39.7
VLDL triglycerides (mg/dl)66.8 ± 57.661.9 ± 46.655.8 ± 31.648.8 ± 33.0
Hemoglobin (gm/dl)14.4 ± 1.513.6 ± 1.9§14.5 ± 1.014.5 ± 1.0
Hematocrit (%)42.0 ± 3.939.8 ± 5.1§42.3 ± 3.042.2 ± 2.9
  • Data are means ± SD.

  • *

    * P < 0.05 vs. baseline;

  • P < 0.05 vs. placebo and insulin at baseline;

  • P < 0.0001 vs. baseline;

  • §

    § P < 0.05 vs. placebo and insulin at week 32.